Client
Michelson Diagnostics Ltd., Kent, United Kingdom
Diagnostic imaging company focused on the diagnosis and follow-up treatment-management of non-melanoma skin cancer (“NMSC”). Utilizing multi-beam optical coherence tomography (“OCT”), VivoSight® OCT enables dermatologists to capture a real-time, continuous scan of a patient’s skin producing high-resolution images of up to 2 millimetres beneath the surface of the skin.
Mandate
Raise follow-on private financing round to enable Michelson to expand the market adaptation and reimbursement of VivoSight® OCT in Europe and the United States.
Investor(s)
Octopus Ventures, Catapult Ventures and angel investors
Transaction
£1,977,779 Series A2
Our Role
Acted as financial advisor to the Board of Directors and management
- Prepared marketing materials and compiled electronic data room
- Designed targeted fund raising campaign approaching a select number of financial and corporate investors.
- Spearheaded negotiation on behalf of the Company with new and existing investors to complete the transaction.
